BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9861837)

  • 21. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.
    Fothergill AW; Rinaldi MG; Sutton DA
    Med Mycol; 2009 Feb; 47(1):41-3. PubMed ID: 19107637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.
    McGinnis MR; Nordoff N; Li RK; Pasarell L; Warnock DW
    Med Mycol; 2001 Aug; 39(4):369-71. PubMed ID: 11556767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antifungal activity of luliconazole against nondermatophytic moulds.
    Maeda J; Koga H; Yuasa K; Neki D; Nanjoh Y; Inagaki K; Reangchainam S; Kampirapap K; Makimura K; Harada K; Tsuboi R
    Med Mycol; 2020 Jul; 58(5):703-706. PubMed ID: 31758690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
    González GM
    Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Mycopathologia; 1998; 141(2):73-7. PubMed ID: 9750338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
    Diekema DJ; Messer SA; Hollis RJ; Jones RN; Pfaller MA
    J Clin Microbiol; 2003 Aug; 41(8):3623-6. PubMed ID: 12904365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
    Radford SA; Johnson EM; Warnock DW
    Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
    Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK; Abraham OC; Chandrasekar PH
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
    Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
    Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].
    García-Martos P; García-Agudo L; Gutiérrez-Calzada J; Ruiz-Aragón J; Saldarreaga A; Marín P
    Enferm Infecc Microbiol Clin; 2005 Jan; 23(1):15-8. PubMed ID: 15701327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
    Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.